| Reimagining the Framework Supporting the Static Analysis of Transporter Drug Interaction Risk; Integrated Use of Biomarkers to Generate Pan‐Transporter Inhibition Signatures | | |
| Assessment of drug–drug interaction potential with EDP ‐305, a farnesoid X receptor agonist, in healthy subjects | Clinical and Translational Science | |
| Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib | Frontiers in Pharmacology | 2021 |
| PET Imaging of ABC Transporters at the Blood-Brain Barrier | | 2021 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2020 |
| Effect of Food on the Pharmacokinetics of Gliclazide 60 mg Modified Release Tablet in Healthy Caucasian Volunteers | Acta Marisiensis - Seria Medica | 2018 |
| Genomics and Drug Transporters and Application in Drug Discovery, Delivery, and Development | | 2018 |
| Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in Japan | Japanese Journal of Clinical Pharmacology and Therapeutics | 2015 |
| Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro CYP Induction Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 | Methods in Pharmacology and Toxicology | 2014 |
| Membrane Transporters in ADME | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| In Vitro Kinetic Characterization of Transporter-Mediated Permeability | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions | Clinical Pharmacology and Therapeutics | 2021 |
| Drug-transporter interaction testing in drug discovery and development | World Journal of Pharmacology | 2013 |
| Irreversible enzyme inhibition kinetics and drug-drug interactions | Methods in Molecular Biology | 2014 |
| Reversible mechanisms of enzyme inhibition and resulting clinical significance | Methods in Molecular Biology | 2014 |
| Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide, a Human Glucagon-Like Peptide-1 Analogue in a Tablet Formulation | Diabetes Therapy | 2021 |
| Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study | Clinical and Translational Science | 2021 |
| Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes | Clinical Pharmacology and Therapeutics | 2020 |
| The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam | Clinical Pharmacology and Therapeutics | 2020 |
| Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin | Clinical and Translational Science | 2020 |
| Test-Retest Repeatability of [F]MC225-PET in Rodents: A Tracer for Imaging of P-gp Function | ACS Chemical Neuroscience | 2020 |
| Drug Interactions in the Liver | | 2020 |
| Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects | Journal of Clinical Pharmacology | 2020 |
| Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor | Xenobiotica | 2020 |
| Precision-engineered reporter cell lines reveal ABCG2 regulation in live lung cancer cells | Biochemical Pharmacology | 2020 |
| Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine | Clinical Pharmacokinetics | 2020 |
| Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole) | Journal of Clinical Pharmacology | 2020 |
| Composite midazolam and 1'-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity | Journal of Pharmacokinetics and Pharmacodynamics | 2020 |
| Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology | International Journal of Molecular Sciences | 2020 |
| Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary | European Journal of Pharmaceutics and Biopharmaceutics | 2020 |
| Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension | AAPS Journal | 2020 |
| Drug–Drug Interaction Studies | | 2020 |
| Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist | Journal of Clinical Pharmacology | 2020 |
| Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6 | Pharmacology Research and Perspectives | 2020 |
| Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions | AAPS Journal | 2020 |
| On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food | AAPS Journal | 2019 |
| Plasma concentrations of pemafibrate with co-administered drugs predicted by physiologically based pharmacokinetic modeling in virtual populations with renal/hepatic impairment | Xenobiotica | 2020 |
| Simplified Method to Determine the Efflux Ratio on P-Glycoprotein Substrates Using Three-Compartment Model Analysis for Caco-2 Cell Assay Data | Pharmaceutical Research | 2019 |
| Effect of Food on the Pharmacokinetics of Quizartinib | Clinical Pharmacology in Drug Development | 2020 |
| Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model | Xenobiotica | 2019 |
| Absorption, disposition, metabolism and excretion of [C]mizagliflozin, a novel selective SGLT1 inhibitor, in rats | Xenobiotica | 2019 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans | Clinical and Translational Science | 2019 |
| Management of Diabetes Mellitus | Contemporary Cardiology | 2019 |
| Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in Mice | Molecular Imaging and Biology | 2019 |
| In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel | European Journal of Drug Metabolism and Pharmacokinetics | 2019 |
